In 2020 the European Haemophilia Consortium (EHC) received funding from the below income sources. The accounts of the EHC are audited by an external auditor and approved by its members during its Annual General Assembly.
The full accounts can be consulted in the EHC 2020 Annual Report.
EHC Funding 2020 - Industry versus non-industry funding
Source of income | Amount in € | % of the total income |
Non-industry | 736,048 | 38% |
Industry | 1,180,730 | 62% |
Highest industry contribution | 256,220 | 13% |
EHC non-industry funding - 2020
Funding source | Amount in € | % of the total income |
EHC membership and other fees | 20,148 | 3% |
EHC Conference income and conference-related fees | 400,900 | 54% |
Volunteer (non-remunerated) contributions | 315,00 | 43% |
Subtotal | 736,048 | 38% |
EHC industry-related funding - 2020
Funding source | Amount in € | % of total income |
Bayer | 52,500 | 3% |
BioMarin | 132,500 | 7% |
Biotest | 20,000 | 1% |
CSL Behring | 75,000 | 4% |
Freeline | 8,500 | 0.4% |
Kedrion | 5,000 | 0.2% |
Novo Nordisk | 45,000 | 2% |
Pfizer | 110,000 | 6% |
Roche | 181,700 | 9% |
Sanofi | 127,080 | 6% |
Sigilon | 3,000 | 0.1% |
Sobi | 221,700 | 11% |
Spark | 30,000 | 1% |
Takeda | 160,000 | 8% |
UniQure | 8,750 | 0.4% |
Subtotal | 1,180,730 | 61% |